Drug intelligence / Profile preview

HUBPE008.1

Development stage: Preclinical
Lead developer: Ambiotech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

HUBPE008.1 is an investigational exosome-based therapy being developed by AM Biotech. It is produced using the company's proprietary Biochemical Pulse Exosome Drug Development Platform, which involves the stimulation of source cells to generate exosomes with specific therapeutic properties. The drug is currently in preclinical development for a broad range of indications, including ophthalmic conditions such as macular degeneration, retinal disease, and dry eye, as well as neurological and auditory disorders like ischemic stroke, hearing loss, and tinnitus. While the specific molecular cargo and targets of HUBPE008.1 have not been disclosed, the therapy aims to leverage the regenerative and anti-inflammatory potential of exosomes to treat degenerative and ischemic diseases.

Beyond the preview

Go deeper on HUBPE008.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUBPE008.1.

Explore the full profile